glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Read the new article from

With both GLP-1s and psychedelics becoming increasingly popular, it will be interesting to see what else is uncovered

The United States is the world's dominant GLP-1 receptor agonist market by an enormous margin, with over 45% of global GLP-1 revenues generated domestically despite representing less than 5% of the world's diabetes and obesity patient population

This is why most experts recommend viewing these as long-term therapies rather than short-term interventions

Crucially, many dont restart

Pearls and Quotes Clinical Implementation of GLP-1 Receptor Agonists GLP-1 agonists work through a variety of mechanisms to counteract metabolic disease